NANOWERT! AUFTRAG VON BAYER!!!! $$$$$$ - 500 Beiträge pro Seite

[sohu]

Bayer HealthCare Selects Tripos to Provide Drug Discovery Software For Its Global Enterprise
Wednesday May 26, 6:00 am ET
Tripos Discovery Informatics Products to Facilitate Bayer`s Drug Development


ST. LOUIS & WUPPERTAL, Germany--(BUSINESS WIRE)--May 26, 2004-- Tripos, Inc. (Nasdaq:TRPS - News), and Bayer HealthCare AG have announced an agreement to deploy Tripos` proprietary discovery informatics software, SYBYL® and UNITY®, globally across Bayer`s drug discovery and development organization. Under the terms of the agreement, Tripos will provide Bayer with license rights to SYBYL and UNITY for its sites in Germany and the United States that are focused on the discovery and development of new therapeutics. Financial terms of the agreement were not disclosed.
The SYBYL computational chemistry and molecular modeling system is the heart of Tripos` discovery software offering, providing the fundamental components for research scientists to understand molecular structure and properties, with a special focus on the creation of new chemical entities. UNITY adds functionality to SYBYL with rapid, conformationally-flexible three-dimensional searching of chemical and biological databases.

"The seamless integration of cheminformatics, pharmacophore modeling and protein structure-based design tools offered by Tripos` software products will help us focus our synthesis efforts on promising compounds," said Dr. Hanno Wild, vice president for medicinal chemistry at Bayer HealthCare.

Dr. Alexander Hillisch, head of computational chemistry at Bayer HealthCare AG, added, "Tripos` ability to offer a complete computational chemistry suite, including sophisticated high-throughput docking programs on the Linux platform, was a critical factor in our choice."

"We are excited to welcome Bayer HealthCare to the list of customers that have embraced our core business strategy of providing one of the most integrated drug discovery offerings available," said Dr. John P. McAlister, president and CEO of Tripos. "Our range of scientific expertise combined with our innovative technological capabilities enables us to provide the breadth of informatics products and services and discovery research offerings our customers need to accomplish their goals."

About Bayer HealthCare AG

Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately 8.9 billion Euros in 2003, is one of the world`s leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. 34,600 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease. Further information on Bayer HealthCare AG can be found at http://www.bayerhealthcare.com/.

About Tripos, Inc.

Tripos (Nasdaq:TRPS - News) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos` Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos` Discovery Research (DR) business, Tripos` medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com/.

This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as "expects," "anticipates," "projects," "estimates," "intends," "plans," "believes," variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.



--------------------------------------------------------------------------------
Contact:
Tripos, Inc.
Jim Rubin, 314-647-8837, ext. 3137
or
Media only:
Waggener Edstrom Bioscience
Tara Gajadhar, 425-638-7000, ext. 5073
[e-mail]



--------------------------------------------------------------------------------
Source: Tripos, Inc.

[Berta Roker]

have announced an agreement to


das soll also ein auftrag sein???

[derdieschnautzelangsamvollhat]

Die Nachfolger von LION Bio bei Bayer.

Lion konnte ja daran nichts verdienen.

[Kautzie]

Hier noch was vom 24.05.2004

-----------------------------------------------------

Tripos Releases LITHIUM 2.0 Desktop Tool For 3-D Chemical Collaboration, Visualization and Decision Support
Tripos Releases LITHIUM 2.0 Desktop Tool For 3-D Chemical Collaboration, Visualization and Decision Support



BW5827 MAY 24,2004 9:31 PACIFIC 12:31 EASTERN



( BW)(MO-TRIPOS)(TRPS) Tripos Releases LITHIUM 2.0 Desktop Tool For3-D Chemical Collaboration, Visualization and Decision Support

Business Editors & Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--May 24, 2004--


Premier Communications Portal Provides Medicinal Chemists With Access To Computational Data

Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discoveryinformatics products and chemistry research, has announced the releaseof LITHIUM(TM) 2.0, a desktop development and delivery system thatprovides a collaborative decision support environment, includingvisualization of 3-D chemical information. LITHIUM streamlinescommunication between frontline life sciences researchers andcomputational chemists. State-of-the-art molecular graphics and auser-friendly interface allow biologists and medicinal chemists toview, understand, interact with and share complex 3-D molecular data,gaining access to vital research information.
"With the introduction of LITHIUM 2.0, Tripos provides not justanother 3-D viewer, but a true enterprise communications system thatempowers any life sciences researcher by providing easy access to insilico information and the ability to understand and share that data,"said Dr. Trevor Heritage, senior vice president and general manager ofdiscovery informatics at Tripos.
"Researchers can now examine new-candidate molecules in biologicalcontext and share that data through Microsoft productivityapplications such as Word, PowerPoint, Excel and Outlook usingstandard OLE cut-and-paste features in Windows to present theirfindings. LITHIUM´s customizability provides a mechanism for researchgroups to gain competitive advantage through deployment of proprietaryinterfaces and applications on top of LITHIUM´s base functionality,"Heritage said.
LITHIUM can be fully customized using Microsoft Windows scriptingwith Microsoft Visual Basic for Applications (VBA). VBA scriptingprovides the ability to distribute specific, task-based interfaces andapplications along with chemical and related data, allowing moreefficient and effective research decision-making. All LITHIUMfunctionality is accessible from VBA.
Product components included in this release are LITHIUM Base, theenterprise, end-user delivery platform for applications andinterfaces, and LITHIUM Developer, the development platform forLITHIUM-based applications and interfaces. LITHIUM Base contains macrorecording and playback capabilities that can automate repetitive tasksand run VBA scripts created using LITHIUM Developer. LITHIUM Developercontains the VBA Interactive Development Environment (IDE), inaddition to all LITHIUM Base functionality. This development toolallows developers to harness the power of LITHIUM to create specificcustom interfaces and applications directly suited to theirorganization´s business needs.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--MRO/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837, ext. 3137 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL MEDICAL DEVICESBIOTECHNOLOGY SOFTWARE PRODUCT SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 18:31 24.05.04

[Kautzie]

Tripos and Crown Partners Form Strategic Alliance to Strengthen Drug Discovery Knowledge Management Solutions
Tripos and Crown Partners Form Strategic Alliance to Strengthen Drug Discovery Knowledge Management Solutions



BW5239 JUN 03,2004 3:02 PACIFIC 06:02 EASTERN



( BW)(MO-TRIPOS)(TRPS) Tripos and Crown Partners Form StrategicAlliance to Strengthen Drug Discovery Knowledge Management Solutions

Business Editors & Health/Medical/High-Tech Writers
BIOWIRE2K

ST. LOUIS & DAYTON, Ohio--(BUSINESS WIRE)--June 3, 2004--


Relationship Brings Industry-Standard Content Management Solutions and Workflow Tools to the Tripos Electronic Notebook Solution

Tripos, Inc. (Nasdaq:TRPS), and Crown Partners LLC todayannounced the formation of a strategic relationship combining CrownPartners´ enterprise-scale content management solution with Tripos´electronic notebook offering. The relationship strengthens the TriposElectronic Notebook(TM) solution by including best-of-breed workflow,collaboration and content management technologies from Documentum, andprovides the electronic notebook with comprehensive support forintellectual property issues involved in the research and developmentlife cycle.
Through a combination of leading expertise in chemistry research,best practice consulting, and the development of innovative drugdiscovery informatics technologies, Tripos implements custom notebooksolutions that best fit the scientific workflow and business goals ofits customers. The core technologies used within the Tripos ElectronicNotebook were developed in collaboration with a leading pharmaceuticalcompany to document and share scientific information, and eliminatestorage of laboratory data in disparate archives.
"Laboratory informatics technologies must seamlessly align with anorganization´s overall knowledge management strategy, especiallyenterprisewide systems like electronic notebooks," said Dr. TrevorHeritage, senior vice president and general manager of DiscoveryInformatics at Tripos. "Crown Partners´ exclusive status as aDocumentum Signature Partner provides Tripos´ clients with a uniquecombination of strength in e-notebooks and content managementtechnologies."
Crown Partners has expertise developing standardized processes andcontent management solutions that leverage the Documentum EnterpriseContent Management platform with extensive experience in scalableprocesses and technologies.
"Crown Partners selects only best-of-breed technology partners todeliver its enterprise content management solutions," said RichardHearn, senior managing partner of Crown Partners Consulting Group."Tripos´ chemistry and informatics experience provides a truly uniqueperspective for the drug discovery sector and is a good addition toour partner strategy."

About Crown Partners Consulting Group

Crown Partners is a leading niche consulting and systemsintegration firm focused on delivering enterprise-scale contentmanagement solutions to the Fortune 1000. We believe our resources arethe best in the industry at making your solution a success. The CrownPartners domain includes leading Content Management packages, such asDocumentum, Document Sciences, Captiva Software, and others. For moreinformation about Crown Partners Services, please call us at937-439-7970, or visit the Crown Partners website atwww.crownpartners.com/.

About Tripos

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--SAM/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Media Only: Waggener Edstrom Bioscience Tara Gajadhar, 425-638-7000, ext. 5073 [e-mail] KEYWORD: OHIO MISSOURI INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWAREHARDWARE MARKETING AGREEMENTS PRODUCT SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 12:02 03.06.04

[CyberCoach]

und was soll der Wert mit Nanotech zu tun haben? Ist doch einfach nur eine software klitsche